Clinical Trial Update: Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma [Phase 1]

View source ↗

Summary

An early-phase (Phase I/II) study of Abraxane in recurrent and refractory lymphoma was terminated. The trial involved non-Hodgkin lymphoma and Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 | Status: TERMINATED